Bedaquiline + Pretomanid + Pyrazinamide
“BPaZ” showed potential to be an improved treatment for the majority of TB patients. The BPaZ regimen consists of bedaquiline (B), pretomanid (also known as PA-824 or Pa), which are two of the newest and most promising drugs for tuberculosis (TB), and pyrazinamide (Z), which is an established drug in the current treatment. BPaZ showed promise to reduce TB treatment to as little as three months.This potential TB treatment regimen was identified by its impressive performance in vitro in TB Alliance’s preclinical regimen identification program. This is an oral regimen, removing the need for injectables as part of MDR-TB treatment.
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)\
- A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005)